Interferon and
Ribavirin
Albumin Interferon
·
80. Safety and efficacy of albinterferon-alfa-2b every four weeks plus
ribavirin for treatment of chronic hepatitis C genotype 2/3.
Interferon and
Ribavirin Therapy – New Studies
The
current standard of care for treating hepatitis C is the combination of
pegylated interferon plus ribavirin. The
two approved pegylated interferon plus ribavirin therapies include:
Pegasys
(pegylated interferon alfa-2a) plus Copegus (ribavirin):
Pre-conference summary: Efficacy (FDA Package Insert): Sustained
virological response rates from two multi-international clinical trials were 44
and 51% for Genotype 1; 70% for Genotype 2 through 6; 82% for Genotype 2 and 3.
·
79.
36 versus 48 weeks of treatment with peginterferon alfa-2a plus ribavirin for
genotype 1/4 patients with undetectable HCV RNA at week 8: Final results of a
randomized multicenter study
·
800. Real-Time PCR Comparison of 48-Week and 72-Week Therapy with
Peginterferon Alfa-2a(40kd) and Ribavirin for Cevr Cases in a Multicenter Clinical Trial: R-Zero Study.
·
813. PACIFIC: A phase III, randomized, multicenter, dose escalation,
efficacy and safety study examining the effects of treatment with peginterferon
alfa-2a in patients with Child’s A or B cirrhosis in chronic hepatitis C virus
infection.
·
823. Continuous Subcutaneous Administration of High-Dose Interferon
Alfa-2b Combined with Ribavirin in Chronic Hepatitis C Patients: A Dose-Finding
And Safety Study in Treatment-Experienced Patients
·
825. Efficacy and safety of an intensified regimen of pegylated interferon
alfa-2a plus ribavirin (RBV) in HCV genotype 1 non-responders: final results of
the SYREN trial.
PegIntron
Pre-conference
summary: Efficacy
(FDA Package Insert): Sustained
virological response rates from one large multi-international clinical trial is
41% for genotype 1; 75%
for genotype 2 and 3
·
130.
Completely individualized treatment durations with peginterferon-alfa-2b and
ribavirin in HCV genotype 1-infected patients and importance of IL28B genotype
(INDIV-2 study).
·
797.
High Correlation Between Week 4 and Week 12 as the
Definition for Null Response to Peginterferon alfa (PEG) plus Ribavirin (R)
Therapy: Results from the IDEAL Trial.
Pegylated Interferon –
General information
·
129.
The IL28B genotype is a major determinant in the induction of a virological
response by high-dose peginterferon and ribavirin in null-responders to
standard-of-care therapy
·
798. Predictive value of IL-28 polymorphism of effect of interferon
therapy in patients with genotype 2a and 2b chronic hepatitis C.
·
814. Individualized Concentration Monitored High Dose Ribavirin in
Combination with Peginterferon to Hepatitis C Genotype 1 Patients with Previous
Nonresponse.
·
816. Impaired Fasting Glucose is Associated with Lower Rates of Sustained
Virologic Response (SVR) in Patients with Genotype 1 Chronic Hepatitis C (CHC):
Retrospective Analysis of the IDEAL Study.
·
817. Impact of PegIntron (PEG) maintenance therapy (MT) on fibrosis
biomarkers (FibroTest[FT]/Fibrosure)
in prior nonresponders with METAVIR fibrosis scores (MFS) of F2/F3: Final
results from the EPIC3 program.
·
822. Analysis of Site Performance in Academic and Community-Based Centers
in the IDEAL Study.
Pegylated Interferon
Lambda (PEG-IFN-ƛ)
Pre-conference summary: Currently in a phase II study combined with
ribavirin to treat HCV genotypes 1 through 4 treatment naïve patients.
·
821. Pegylated Interferon Lambda (PEG-IFN-λ) Phase 2 Dose-Ranging,
Active-Controlled Study in Combination with Ribavirin (RBV) for Treatment-Naïve
HCV Patients (Genotypes 1, 2, 3 or 4): Safety, Viral Response, and Impact of
IL-28B Host Genotype through Week 12.
·
830. Pharmacokinetics of PEG-Interferon Lambda (PEG-IFN-λ) Following
Fixed Dosing in Treatment-Naïve Hepatitis C Subjects (Single Dose Interim Data
from a Dose-Ranging Phase 2a Study) (Updated October 31, 2010)
·
831. The Effect of Treatment Group, HCV Genotype,
and IL28B Genotype on Early HCV Viral Kinetics in a Phase 2a Study of
PEG-Interferon Lambda (PEG-IFN-λ) in Hepatitis C Patients. (Updated October 31,
2010)
·
1854. In Vitro Activity of the Combination of Pegylated Interferon-Lambda
(PEG-IFN-λ) with Direct-Acting Antivirals in the HCV Replicon Model.
·
1868. Interferon lambda
plays a critical role on antiviral response by hepatotropic
inducer of innate immunity in human hepatocyte.